Intrastromal anti-VEGF injection for corneal neovascularization
Official title: Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07329686 · Data updated 2026-11-12
We will test whether injecting anti-VEGF medicine into the cornea helps adults with corneal neovascularization caused by herpes simplex keratitis.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | October 2026 |
| Study ends | October 2026 |
| Registry record updated | January 9, 2026 |
| Trial ID | NCT07329686 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with herpes simplex keratitis who have corneal neovascularization, have not previously received anti-VEGF treatment or corneal surgery, and can consent and attend follow-up visits.
✕Probably not a fit
Patients at risk of corneal perforation, with severe ocular surface dryness, major systemic immune or nervous system diseases, or recent systemic immunosuppressant use are unlikely to benefit or may be excluded for safety.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 1/2, single-center interventional trial delivers anti-VEGF directly into the corneal stroma alongside standard topical antiviral drops in adults with neovascularization from herpes simplex keratitis. Participants receive targeted intrastromal injections and are followed at scheduled visits to monitor safety, changes in vessel growth, and visual outcomes compared with conventional topical antiviral therapy. The approach leverages high local drug concentration and prolonged action to limit systemic exposure while tracking ocular adverse events such as infection, inflammation, or corneal integrity issues. The sponsor is the Second Affiliated Hospital, School of Medicine, Zhejiang University, and the protocol focuses on establishing preliminary safety and signals of efficacy.
Why it matters
Potential benefit: If successful, this targeted injection could reduce corneal blood vessel growth and improve or stabilize vision with fewer systemic side effects.
How similar studies have gone: Intrastromal injections have been used preliminarily for fungal keratitis and neurotrophic corneal disease with promising early results, but intrastromal anti-VEGF for HSK-related neovascularization is relatively novel with limited published data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis: Patients who meet the diagnostic criteria for Herpes Simplex Virus (HSV) keratitis with neovascularization. * Age: Adults aged 18 years or older. * Previous Treatment: Patients who have not undergone other anti-VEGF treatments or corneal surgeries. * Informed Consent: Patients who are capable of understanding and signing an informed consent form, agreeing to participate in the entire study process and to follow the study's follow-up schedule and treatment plan. * Other: Additional criteria as deemed necessary by the investigator. Exclusion Criteria: * Risk of Corneal Perforation: Patients at risk of corneal perforation. * Severe Ocular Surface Dryness: Patients with severe dry eye syndrome. * Systemic Diseases: Patients with systemic diseases that may affect the nervous or immune systems, such as diabetes, rheumatoid arthritis, autoimmune diseases, etc. * Recent Use of Systemic Immunosuppressants: Patients who have recently used systemic immunosuppressive agents. * Poor Compliance: Patients who are unable to follow up on time or adhere to the treatment plan. * Pregnancy or Lactation: Pregnant or nursing women, as their physiological state may affect study outcomes. * Allergy History: Patients with a history of allergies to the study medication or related components. * Other Reasons: Patients deemed by the investigator to have other reasons making them unsuitable for participation in the trial.
Where it's running
-
1 Xihu Avenue, Shangcheng District,Hangzhou, Zhejiang,China,Hangzhou, Zhejiang Completed
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Xiuming Jin
- Email: lzyjxm@zju.edu.cn
- Phone: 8613989455778
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment of corneal neovascularization using riboflavin photo-activation
This study is testing if a light treatment with riboflavin can help people with corneal neovascularization feel better and improve their eye health.
-
Intelligent Video Laryngoscope to Help Emergency Intubations
A smart video laryngoscope with AI is tested to help doctors place tubes in critically ill adults needing emergency intubation.
-
Understanding anxiety, depression, and bipolar disorder over time in China
This study tests how anxiety, depressive, and bipolar symptoms change over three years to find patterns that help with earlier recognition and prediction in people aged 12–55.
-
Ultrasound-guided nasal bone fracture reduction
This study tests whether using ultrasound to guide nasal bone fracture reduction can improve accuracy and outcomes for people with recent nasal injuries.
-
Simplified Tranexamic Acid Regimen for Trauma with Hemorrhage
This trial tests a simplified TXA dosing approach to see if it safely helps adults with major trauma and significant bleeding.
-
Retrobulbar glucocorticoid injection for retinal light injury
This study tests whether giving a retrobulbar glucocorticoid injection helps people who have retinal damage from bright light.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.